Unia Europejska - maltański - EMA (European Medicines Agency)

abbvie deutschland gmbh & co. kg - dexamethasone - macular edema; uveitis - ophthalmologicals, other ophthalmologicals - ozurdex huwa indikat għall-kura ta ' pazjenti adulti b'edema makulari tad-dijabete li ġejjin jew fergħa tar-retina-okklużjoni tal-vina (brvo) jew ċentrali tar-retina-okklużjoni tal-vina (crvo). ozurdex huwa indikat għall-kura ta 'pazjenti adulti b'infjammazzjoni ta' l-segment posterjuri ta ' l-għajn l-preżentazzjoni kif noninfectious uveite. ozurdex huwa indikat għall-kura ta 'pazjenti adulti b'indeboliment tal-vista minħabba ta' edima makulari dijabetika (dme) li huma pazjenti psewdoafakiċi jew li huma kkunsidrati bħala mhux biżżejjed li jirrispondu għal, jew li mhux tajbin għall-non-terapija tal-kortikosterojdi.

Unia Europejska - maltański - EMA (European Medicines Agency)

neovii biotech gmbh - catumaxomab - ascites; cancer - aġenti antineoplastiċi oħra - removab huwa indikat għat-trattament intraperitoneali ta 'axxiti malinni f'pazjenti b'karċinomi pożittivi għal epcam fejn it-terapija standard mhijiex disponibbli jew m'għadhiex possibbli.

Unia Europejska - maltański - EMA (European Medicines Agency)

sun pharmaceutical industries europe b.v. - temozolomide - glioma; glioblastoma - aġenti antineoplastiċi - temozolomide xemx huwa indikat għall-kura ta': pazjenti adulti li jkunu għadhom kif ġew dijanjostikati b'i glijoblastoma multiforme flimkien mar-radjuterapija (rt) u wara bħala kura b'monoterapija;it-tfal mill-età ta ' tliet snin fuq, adolexxenti, u pazjenti adulti bi glijoma malinna, bħal glioblastoma multiforme jew astroċitoma anaplastika, li jerġgħu jirkadu jew progressjoni wara terapija standard.

Unia Europejska - maltański - EMA (European Medicines Agency)

dr. falk pharma gmbh - budesonide - mard esophageal - antidiarrheals, intestinali anti-infjammatorji / antiinfective aġenti - jorveza huwa indikat għall-kura ta 'esofaġite eosinophilic (eoe) f'adulti (ta' età akbar minn 18-il sena).

Unia Europejska - maltański - EMA (European Medicines Agency)

esteve pharmaceuticals gmbh - thiotepa - hematopoietic stem cell transplantation; neoplasms - aġenti antineoplastiċi - thiotepa riemser is indicated, in combination with other chemotherapy medicinal products:with or without total body irradiation (tbi), as conditioning treatment prior to allogeneic or autologous haematopoietic progenitor cell transplantation (hpct) in haematological diseases in adult and paediatric patients;when high dose chemotherapy with hpct support is appropriate for the treatment of solid tumours in adult and paediatric patients. thiotepa riemser is indicated, in combination with other chemotherapy medicinal products:with or without total body irradiation (tbi), as conditioning treatment prior to allogeneic or autologous haematopoietic progenitor cell transplantation (hpct) in haematological diseases in adult and paediatric patients;when high dose chemotherapy with hpct support is appropriate for the treatment of solid tumours in adult and paediatric patients.

Unia Europejska - maltański - EMA (European Medicines Agency)

axunio pharma gmbh - pirfenidone - fibrożi pulmonari idjopatika - immunosoppressanti - pirfenidone aet is indicated in adults for the treatment of mild to moderate idiopathic pulmonary fibrosis (ipf).

Unia Europejska - maltański - EMA (European Medicines Agency)

aop orphan pharmaceuticals gmbh - sugammadex sodium - imblokk neuromuskolari - il-prodotti terapewtiċi l-oħra kollha - it-treġġigħ lura ta 'imblokk newromuskolari kkawżat minn rocuronium jew vecuronium. for the paediatric population: sugammadex is only recommended for routine reversal of rocuronium induced blockade in children and adolescents aged 2 to 17 years.

Unia Europejska - maltański - EMA (European Medicines Agency)

idorsia pharmaceuticals deutschland gmbh - daridorexant hydrochloride - sleep inizjattiva u maintenance disorders - psikolettiċi - quviviq is indicated for the treatment of adult patients with insomnia characterised by symptoms present for at least 3 months and considerable impact on daytime functioning.

Unia Europejska - maltański - EMA (European Medicines Agency)

boehringer ingelheim international gmbh - linagliptin - diabetes mellitus, tip 2 - drogi użati fid-dijabete - trajenta huwa indikat fit-trattament tad-dijabete tat-tip 2 mellitus biex itejbu l-kontroll gliċemiku fl-adulti:kif monotherapyin pazjenti li mhumiex ikkontrollati biżżejjed bid-dieta u l-eżerċizzju waħidhom u li għalihom metformin mhux adattat minħabba l-intolleranza, jew kontra-indikat minħabba l-indeboliment tal-kliewi. bħala kombinazzjoni therapyin flimkien ma 'metformin meta d-dieta u l-eżerċizzju flimkien ma' metformin waħdu ma jipprovdux kontroll gliċemiku adegwat. f'kombinazzjoni ma ' sulphonylurea u metformin meta d-dieta u l-eżerċizzju flimkien ma doppju it-terapija b'dawn il-prodotti mediċinali ma jipprovdux kontroll gliċemiku adegwat. flimkien ma 'l-insulina bi jew mingħajr metformin, meta dan ir-reġim waħdu, ma' dieta u eżerċizzju, ma jipprovdux kontroll gliċemiku adegwat.

Unia Europejska - maltański - EMA (European Medicines Agency)

sun pharmaceutical industries europe b.v. - atosiban (as acetate) - twelid prematur - oħra gynecologicals - tractocile huwa indikat biex jittardja t twelid qabel iż-żmien f'nisa tqal nisa adulti bil:regolari tal-kontrazzjonijiet ta'l-utru ta 'mill-inqas 30 sekonda' tul b'rata ta' ≥ 4 kull 30 minuta;twessigħ ċervikali minn 1 sa 3 cm (0-3 snin għall-nulliparas) u effacement ta '≥ 50%;età ta ' ġestazzjoni minn 24 sa 33 ġimgħa magħluqa;normali rata tal-qalb tal-fetu.